Decision making for transjugular intrahepatic portosystemic stent shunt in refractory ascites and variceal bleeding: MELD, or not MELD, that is the question.
Ascites
/ complications
Bilirubin
Decision Making
End Stage Liver Disease
/ complications
Esophageal and Gastric Varices
/ complications
Female
Gastrointestinal Hemorrhage
/ complications
Humans
Liver Cirrhosis
/ complications
Male
Portasystemic Shunt, Transjugular Intrahepatic
/ adverse effects
Retrospective Studies
Stents
Treatment Outcome
Journal
European journal of gastroenterology & hepatology
ISSN: 1473-5687
Titre abrégé: Eur J Gastroenterol Hepatol
Pays: England
ID NLM: 9000874
Informations de publication
Date de publication:
01 12 2021
01 12 2021
Historique:
pubmed:
25
11
2020
medline:
12
4
2022
entrez:
24
11
2020
Statut:
ppublish
Résumé
The model of end-stage liver disease (MELD) score has been shown to predict 3-month prognosis following transjugular intrahepatic portosystemic stent shunt (TIPS) in liver cirrhosis; however, that score was derived from a mixed cohort, including patients with refractory ascites and variceal bleeding. This study re-evaluates the role of the MELD score and focuses on differences between both groups of patients. A total of 301 patients (192 male and 109 female) received TIPS, 213 because of refractory ascites and 88 because of variceal bleeding. Univariate and multivariate Cox analyses were performed to identify predictors of mortality and area under the receiver operator characteristics (AUROC) were used to assess the prognostic capacity of the MELD score and of the results of predictors of the multivariate analyses. In refractory ascites, age, bilirubin and albumin were independent predictors of mortality. In variceal bleeding, emergency TIPS during ongoing bleeding, concomitant grade III ascites, history of hepatic encephalopathy, spontaneous bacterial peritonitis, bilirubin and platelet count proved significant. AUROCs of the MELD score for 3-month survival yielded 0.543 and 0.836 for refractory ascites and variceal bleeding, respectively (P < 0.001). For 1-year survival, the respective AUROCs yielded 0.533 and 0.767 (P < 0.001). In contrast to MELD, the AUROCs based on the calculated risk scores of this study resulted in 0.660 and 0.876 for 3-month survival, and 0.665 and 0.835 for 1-year survival in patients with ascites and variceal bleeding, respectively. In refractory ascites, the prognostic capability of MELD is significantly inferior compared to variceal bleeding. The results of our multivariate analyses and AUROC calculations corroborate the impact of different prognostic variables in patients undergoing TIPS for ascites and variceal bleeding.
Identifiants
pubmed: 33230020
pii: 00042737-202112001-00026
doi: 10.1097/MEG.0000000000002009
pmc: PMC8734626
doi:
Substances chimiques
Bilirubin
RFM9X3LJ49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e214-e222Informations de copyright
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Diagn Interv Imaging. 2018 Mar;99(3):163-168
pubmed: 29154015
Semin Intervent Radiol. 2014 Sep;31(3):248-51
pubmed: 25177085
Ann Hepatol. 2015 May-Jun;14(3):380-8
pubmed: 25864219
World J Gastroenterol. 2016 Jul 7;22(25):5780-9
pubmed: 27433091
Dig Dis Sci. 2017 Feb;62(2):534-542
pubmed: 27154510
Cardiovasc Intervent Radiol. 2018 Jul;41(7):1029-1034
pubmed: 29516241
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
Ann Hepatol. 2016 Mar - Apr;15(2):215-221
pubmed: 31196403
Lancet Gastroenterol Hepatol. 2019 Aug;4(8):587-598
pubmed: 31153882
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Hepatol Commun. 2019 Jan 22;3(3):340-347
pubmed: 30984902
N Engl J Med. 1994 Jan 20;330(3):165-71
pubmed: 8264738
Eur J Gastroenterol Hepatol. 2018 Dec;30(12):1441-1446
pubmed: 30048333
J Hepatol. 2010 Sep;53(3):397-417
pubmed: 20633946
N Engl J Med. 2010 Jun 24;362(25):2370-9
pubmed: 20573925
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
PLoS One. 2019 May 23;14(5):e0217442
pubmed: 31120995
J Vasc Interv Radiol. 2010 Feb;21(2):218-23
pubmed: 20123207
Gut. 2019 Jul;68(7):1297-1310
pubmed: 30415233